natgillin/translations-raw huggingface dataset:
In the QD group, 6/75 (8%) patients demonstrated new primary protease inhibitor mutations (codons 30, 32, 48, 50, 82, 84, 90), as did 12/77 (16%) patients in the BID group.
U QD grupi kod 6/75 (8%) bolesnika su zabilježene nove primarne mutacije inhibitora proteaze (kodoni 30, 32, 48, 50, 82, 84, 90) kao i kod 12/77 (16%) bolesnika iz BID grupe.
In the rabbit, sodium aminosalicylate had no effects on embryofetal development; however, the doses evaluated were below those proposed clinically.
U kunića, natrij aminosalicilat nije imao učinaka na embrio-fetalni razvoj, no ispitivane doze su bile manje od klinički predloženih.
In the RAISE study, in mCRC patients treated with ramucirumab plus FOLFIRI, the most frequent (≥1%) ADR that led to the discontinuation of ramucirumab was proteinuria (1.5%).
Najčešća nuspojava (≥ 1%) koja je dovela do prekida primjene ramucirumaba u bolesnika s metastatskim kolorektalnim rakom liječenih ramucirumabom plus protokolom FOLFIRI u ispitivanju RAISE bila je proteinurija (1,5%).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21 % vs 8 %, respectively – chi-square p=0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p=0.0063).
U randomiziranom ispitivanju s aktivnom kontrolom je PFS nakon 6 mjeseci bio značajno veći u skupini koja je primala TMZ nego u skupini koja je primala prokarbazin (21% naspram 8%; hi-kvadrat p = 0,008), uz medijan PFS-a od 2,89 mjeseci u prvoj odnosno 1,88 mjeseci u drugoj skupini (log rang p = 0,0063).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than for procarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
U randomiziranom ispitivanju s aktivnom kontrolom je PFS nakon 6 mjeseci bio značajno veći u skupini koja je primala TMZ nego u skupini koja je primala prokarbazin (21% naspram 8%; hi-kvadrat p = 0,008), uz medijan PFS-a od 2,89 mjeseci u prvoj odnosno 1,88 mjeseci u drugoj skupini (log rang p = 0,0063).
In the randomised active-controlled trial, the PFS at 6 months was significantly greater for TMZ than forprocarbazine (21% vs 8%, respectively – chi-square p = 0.008) with median PFS of 2.89 and 1.88 months respectively (log rank p = 0.0063).
U randomiziranom ispitivanju s aktivnom kontrolom je PFS nakon 6 mjeseci bio značajno veći u skupini koja je primala TMZ nego u skupini koja je primala prokarbazin (21% naspram 8%; hi-kvadrat p = 0,008), uz medijan PFS-a od 2,89 mjeseci u prvoj odnosno 1,88 mjeseci u drugoj skupini (log rang p = 0,0063).
In the randomised period of the pivotal studies, anaemia was less frequent in PV patients than in MF patients (43.6% versus 82.4%).
U randomiziranom razdoblju ključnih ispitivanja, anemija je bila manje učestala u bolesnika s PV-om nego u bolesnika s MF-om (43,6% naspram 82,4%).
In the randomised period of the pivotal studies, the rate of patients experiencing thrombocytopenia was lower in PV (24.5%) patients compared to MF (69.8%) patients.
U randomiziranom razdoblju ključnih ispitivanja, stopa bolesnika u kojih se pojavila trombocitopenija bila je niža kod bolesnika s PV-om (24,5%) u usporedbi s bolesnicima s MF-om (69,8%).
In the randomised period of the pivotal study in PV patients, bleeding events (including intracranial and gastrointestinal, bruising and other bleeding events) were reported in 20% of patients treated with Jakavi and 15.3% patients receiving best available therapy.
U randomiziranom razdoblju ključnog ispitivanja u bolesnika s PV-om, događaji krvarenja (uključujući intrakranijalno i gastrointestinalno, stvaranje modrica i druge događaje krvarenja) bili su zabilježeni u 20% bolesnika liječenih Jakavijem te u 15,3% bolesnika koji su primali najbolju dostupnu terapiju.
In the randomised period of the pivotal study in PV patients, neutropenia was reported in two patients (1.8%) of which one patient developed CTCAE grade 4 neutropenia.
U randomiziranom razdoblju ključnog ispitivanja u bolesnika s PV-om neutropenija je bila prijavljena u dva bolesnika (1,8%), od čega se u jednoga bolesnika razvila neutropenija stupnja 4 prema
In the randomised period of the pivotal study in PV patients, one (0.9%) CTCAE grade 3 and no grade 4 urinary tract infection was reported.
U randomiziranom razdoblju ključnog ispitivanja u bolesnika s PV-om prijavljena je jedna (0,9%) infekcija mokraćnog sustava stupnja 3 i niti jedna stupnja 4 prema CTCAE-u.
In the randomised period of the pivotal study in PV patients, the mean systolic blood pressure increased by 0.65 mmHg in the Jakavi arm versus a decrease of 2 mmHg in the BAT arm.
U randomiziranom periodu ključnog ispitivanja u bolesnika s PV-om, srednji sistolički krvni tlak povećao se za 0,65 mmHg u skupini koja je primala Jakavi naspram smanjenja od 2 mmHg u skupini koja je primala najbolju dostupnu terapiju.
In the randomised period of the two pivotal studies, COMFORT-I and COMFORT-II, the median duration of exposure to Jakavi was 10.8 months (range 0.3 to 23.5 months).
U randomiziranom razdoblju dvaju ključnih ispitivanja, COMFORT-I i COMFORT-II, medijan trajanja izloženosti Jakaviju bio je 10,8 mjeseci (raspon 0,3 do 23,5 mjeseci).
In the rare cases when this is inappropriate, dose reduction of stavudine may be considered, while the symptoms of peripheral neuropathy are under close monitoring and satisfactory virological suppression is maintained.
U rijetkim slučajevima kada navedeno nije moguće, može se razmotriti smanjivanje doze stavudina uz redovito praćenje simptoma periferne neuropatije, i dok je održana zadovoljavajuća virološka supresija.
In the rasagiline clinical program overall, 1,361 patients were treated with rasagiline for
U kliničkom programu s razagilinom je ukupno 1361 bolesnik bio liječen razagilinom kroz
In the rat carcinogenicity study, benign tumours were found in the small bowel and the extrahepatic bile ducts.
U ispitivanju kancerogenosti na štakorima pronađeni su benigni tumori u tankom crijevu i ekstrahepatičnim žučnim vodovima.
In the rat fertility study, dexmedetomidine had no effect on male or female fertility.
U ispitivanju plodnosti štakora, deksmedetomidin nije utjecao na mušku ili žensku plodnost.
In the rat pre- and postnatal development study, a decrease in pup survival occurred between birth and postnatal day 21 at doses of 60 mg/kg/day or higher (5 times the expected human clinical exposure).
Ispitivanja pre- i postnatalnog razvoja kod štakora pokazala su smanjenje u stopi preživljenja mladunčadi u razdoblju između poroda i 21. dana nakon poroda pri dozama od 60 mg/kg/dan ili više (5 puta više od očekivane kliničke izloženosti kod ljudi).
In the rat, no adverse effects were observed in a pre- and post-natal development study at maternal plasma exposure (AUC) similar to humans and exposure in the offspring 3-fold higher than in adult humans.
U štakora, nisu uočeni štetni učinci u pre- i postnatalnom razvojnom ispitivanju pri maternalnoj izloženosti u plazmi (AUC) koji su slični ljudskim a izloženost u mladunčadi 3-puta viša nego u odraslih ljudi.
In the rat, subcutaneous administration at the maximum dose, 200 µg/kg/day, caused an increase in embryofetal death and reduced the fetal body weight.
Kod štakora je supkutana primjena s maksimalnom dozom, 200 µg/kg/dnevno, dovelo do povećanja embriofetalne smrtnosti i smanjenja fetalne tjelesne mase.
In the RCC Clinical Trial 1, hyperlipaemia was reported as an adverse event in 27% of patients.
U RCC kliničkom ispitivanju 1, hiperlipemija je bila zabilježena kao štetni događaj u 27% bolesnika.
In the RCC Clinical Trial, a Phase 3 clinical trial for renal cell carcinoma, 26% of patients reported hyperglycaemia as an adverse event.
U RCC kliničkom ispitivanju - kliničkom ispitivanju faze III karcinoma bubrežnih stanica, 26% bolesnika prijavilo je hiperglikemiju kao štetni događaj.
In the RE-MODEL trial (knee replacement) treatment was for 6-10 days and in the RE-NOVATE trial (hip replacement) for 28-35 days.
U ispitivanju pod nazivom RE-MODEL (ugradnja endoproteze koljena) liječenje je trajalo 6 – 10 dana, a u ispitivanju pod nazivom RE-NOVATE (ugradnja endoproteze kuka) 28 – 35 dana.
In the RE-SONATE study, which compared dabigatran etexilate to placebo, the rate of MI was 0.1 % for patients who received dabigatran etexilate and 0.2 %for patients who received placebo (see section 4.4.).
U ispitivanju RE-SONATE, koje je uspoređivalo dabigatraneteksilat s placebom, stopa IM-a je bila 0,1% za bolesnike koji su primali dabigatraneteksilat i 0,2 % za bolesnike koji su primali placebo (vidjeti dio 4.4).
In the RE-SONATE study, which compared dabigatran etexilate to placebo, the rate of MI was 0.1% for patients who received dabigatran etexilate and 0.2 % for patients who received placebo (see section 4.4).
U ispitivanju RE-SONATE, koje je uspoređivalo dabigatraneteksilat s placebom, stopa IM-a je bila 0,1% za bolesnike koji su primali dabigatraneteksilat i 0,2 % za bolesnike koji su primali placebo (vidjeti dio 4.4).
In the re-treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus <1% (1/222) on maintenance therapy.
U skupini u kojoj je ponovljena uvodna shema liječenja ozbiljnu reakciju na infuziju razvilo je 4% (8/219) bolesnika u odnosu na
In the REACH study, 112 patients (6 to 17 years, median age 13.0 years) with moderate to severe, active Crohn’s disease (median paediatric CDAI of 40) and an inadequate response to conventional therapies were to receive 5 mg/kg infliximab at weeks 0, 2, and 6.
U kliničkom ispitivanju REACH, 112 bolesnika (raspon dobi: 6-17 godina, medijan 13 godina) s umjerenom do teškom, aktivnom Crohnovom bolešću (srednji pedijatrijski CDAI bio je 40) i neodgovarajućim odgovorom na konvencionalnu terapiju primilo je infliksimab u dozi od 5 mg/kg u 0., 2. i 6. tjednu.
In the RECOURSE clinical trial, treatment-related proteinuria occurred more frequently in Lonsurf- treated patients (2.8%) compared to those receiving placebo (1.5%), all of which were Grade 1 or 2 in severity (see section 4.4).
U kliničkom ispitivanju RECOURSE, proteinurija povezana s liječenjem češće je zabilježena kod bolesnika liječenih Lonsurfom (2,8%) u usporedbi s placebom (1,5%), a po težini su sve bile 1. ili 2. stupnja (vidjeti dio 4.4).
In the RECOURSE study, 9.4% of patients in the Lonsurf group received G-CSF mainly for therapeutic use.
U RECOURSE ispitivanju je 9,4% bolesnika liječenih Lonsurfom primilo G-CSF u terapijske svrhe.
In the registry study of patients with PNH who had never had a blood transfusion, patients treated with Soliris had clinically meaningful reductions in levels of lactate dehydrogenase (LDH) after 6 months of treatment, indicating reduced breakdown of red blood cells.
U ispitivanju koje se temelji na podacima iz registra bolesnika oboljelih od PNH-a koji nikad nisu imali transfuziju krvi, kod bolesnika liječenih lijekom Soliris klinički značajno smanjile su se razine laktat dehidrogenaze (LDH) nakon šest mjeseci liječenja, ukazujući na smanjenje razgradnje crvenih krvnih stanica.
In the relapsed/refractory CLL study grade 3/4 thrombocytopenia was reported in 11% of patients in the R-FC group compared to 9% of patients in the FC group.
U ispitivanju relapsirajućeg/refraktornog KLL-a trombocitopenija stupnja 3/4 prijavljena je u 11% bolesnika u skupini koja je primala R-FC u usporedbi s 9% bolesnika u skupini koja je primala FC.
In the relapsed/refractory study, the median progression-free survival (primary endpoint) was 30.6 months in the R-FC group and 20.6 months in the FC group (p=0.0002, log--rank test).
U ispitivanju relapsirajućeg/refraktornog KLL-a medijan preživljenja bez progresije bolesti (primarna mjera ishoda) bio je 30,6 mjeseci u skupini R-FC i 20,6 mjeseci u skupini FC (p = 0,0002, log-rang test).
In the remaining non-dialysis studies, a total of 3 serious adverse reactions reported in 2 patients were gastrointestinal in nature (gastrointestinal ulcer, gastric polyps and colonic polyps).
U preostalim ispitivanjima bolesnika koji se ne liječe dijalizom prijavljene su ukupno 3 ozbiljne nuspojave u 2 bolesnika i one su bile gastrointestinalnog karaktera (gastrointestinalni ulkus, želučani polipi i polipi kolona).
In the renal cell carcinoma study, patients who took Afinitor lived for an average of 4.9 months without the disease getting worse, compared with 1.9 months for the patients who took placebo.
U ispitivanju bolesnika s karcinomom bubrežnih stanica, bolesnici koji su uzimali lijek Afinitor živjeli su prosječno 4,9 mjeseci bez pogoršanja bolesti u usporedbi s 1,9 mjeseci u slučaju bolesnika koji su uzimali placebo.
In the renal impairment population, lomitapide was only studied in patients with end-stage renal disease (ESRD).
U populaciji s oštećenjem funkcije bubrega lomitapid je ispitan samo u bolesnika s terminalnim stadijem kroničnog bubrežnog zatajenja (ESRD).
In the repeated dose toxicity studies, mild reversible liver changes were observed in rats starting at about 3 times the clinical exposure.
U ispitivanjima toksičnosti ponavljanih doza primijećene su blage reverzibilne promjene jetre kod štakora nakon izloženosti tri puta veće od kliničke izloženosti.
In the ropinirole group, patients were titrated to their optimal dose up to a maximum of 24 mg/day over 13 weeks.
U ropinirol skupini bolesnici su titrirani do optimalne doze od najviše 24 mg/dan kroz 13 tjedana.
In the RUTH study, leg cramps were observed in 12.1 % of raloxifene-treated patients and 8.3 % of placebo-treated patients.
U RUTH ispitivanju uočena je pojava grčeva u nogama u 12,1 % bolesnica koje su liječene raloksifenom i 8,3 % bolesnica koje su dobivale placebo.
In the SAILING study, virologic suppression (HIV-1 RNA <50 copies/mL) in the Tivicay arm (71%) was statistically superior to the raltegravir arm (64%), at Week 48 (p=0.03).
U ispitivanju SAILING je virološka supresija (HIV-1 RNK < 50 kopija/m) u skupini koja je primala Tivicay (71%) nakon 48 tjedana bila statistički superiorna u odnosu na skupinu koja je primala raltegravir (64%) (p=0,03).
In the sALCL study, 86% of patients (50 out of 58) responded partially or completely to treatment and this response was complete for 59% of them (34 out of 58).
U ispitivanju sALCL-a, 86 % bolesnika (50 od 58) djelomično je ili u potpunosti odgovorilo na liječenje, a potpuni odgovor zabilježen je kod 59 % bolesnika (34 od 58).
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima prijavljene su cerebrovaskularni štetni događaji (CV štetni događaj, primjerice moždani udar, prolazni ishemijski napad), uključujući smrtne slučajeve.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima prijavljeni su cerebrovaskularni štetni događaji ( CV štetni događaji, primjerice moždani udar, prolazni ishemijski napad), uključujući smrtne slučajeve.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima zabilježeni su cerebrovaskularni štetni događaji (CV CV štetni događaji, primjerice moždani udar, prolazni ishemijski napad) uključujući smrtne slučajeve.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima zabilježeni su cerebrovaskularni štetni događaji (CV štetni događaji,, primjerice moždani udar, prolazni ishemijski napad) uključujući smrtne slučajeve.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima zabilježeni su cerebrovaskularni štetni događaji (štetni događaji, primjerice moždani udar, prolazni ishemijski napad) uključujući smrtne slučajeve.
In the same clinical trials, cerebrovascular adverse events (CVAE e.g., stroke, transient ischemic attack), including fatalities, were reported.
U istim kliničkim ispitivanjima zabilježeni su neželjeni cerebrovaskularni događaji (CV događaji, primjerice moždani udar, prolazni ishemijski napad) uključujući smrtne slučajeve.
In the same study another group of adults aged 50-59 years and another group of adults aged 18-49 years received a single dose of Prevenar 13.
U istom je ispitivanju druga skupina odraslih u dobi od 50 do 59 godina i još jedna skupina odraslih ≥ 18 godina do 49 godina primila jednu dozu Prevenara 13.
In the same study as above, administration of an antacid (aluminium hydroxide/magnesium hydroxide/simethicone) 2 hours before or after a single 400 mg dose of Tasigna also did not alter nilotinib pharmacokinetics.
U istome, prethodno spomenutome ispitivanju primjena antacida (aluminij hidroksid/magnezij hidroksid/simetikon) 2 sata prije ili poslije jednokratne doze od 400 mg Tasigne također nije promijenila farmakokinetiku nilotiniba.
In the same study, a single 1.5 mg dose of dulaglutide appeared to increase maximal insulin secretion from the β-cells, and to enhance β-cell function in subjects with type 2 diabetes mellitus as compared with placebo.
U istom je ispitivanju jedna doza dulaglutida od 1,5 mg naizgled povećala maksimalno lučenje inzulina iz β-stanica i poboljšala funkciju β-stanica u bolesnika sa šećernom bolešću tipa 2 u odnosu na placebo.
In the same study, a statistically significant increase was reported in the incidence of pulmonary embolism (0.7% in the placebo group versus 1.1% in the fenofibrate group; p = 0.022) and a statistically non-significant increase in deep vein thromboses (placebo: 1.0 % [48/4,900 patients] versus fenofibrate 1.4% [67/4,895 patients]; p = 0.074).
U istom ispitivanju prijavljeno je statistički značajno povećanje incidencije plućne embolije (0,7% u placebo skupini naspram 1,1% u skupini na fenofibratu; p=0,022) i statistički neznačajno povećanje duboke venske tromboze (placebo: 1,0% [48/4900 bolesnika] naspram fenofibrata 1,4% [67/4895]; p=0,074).
In the same study, following 6 ml of glycerol phenylbutyrate for 3 days (TID), mean Cmax and AUC were 100 mcg/ml and 1400 mcg•h/ml for PBA and 65 mcg/ml and 2064 mcg•h/ml for PAA, respectively.
U istom ispitivanju, nakon 6 ml glicerolfenilbutirata tijekom 3 dana (3 puta dnevno), srednji Cmax i AUC bili su 100 μg/ml i 1400 μg•h/ml za PBA, odnosno 65 μg/ml i 2064 μg•h/ml za PAA.
In the SAVOR study subgroups over 65 and over 75 years of age, efficacy and safety was consistent with the overall study population.
U ispitivanju SAVOR su djelotvornost i sigurnost u podskupinama bolesnika starijih od 65 godina i starijih od 75 godina bile u skladu s onima zabilježenima u cjelokupnoj ispitivanoj populaciji.
In the SAVOR study subgroups over 65 and over 75 years of age, efficacy and safety was consistent with the overall study population.
U ispitivanju SAVOR su djelotvornost i sigurnost u podskupinama bolesnika starijih od 65 godina i starijih od 75 godina bile u sukladu s onima zabilježenima u cjelokupnoj ispitivanoj populaciji.
In the second CABG surgery study, four pre-specified event categories were evaluated (cardiovascular/thromboembolic; renal dysfunction/renal failure; upper GI ulcer/bleeding; surgical wound complication).
U drugom ispitivanju kod operacije ugradnje arteriokoronarne premosnice procjenjivane su četiri unaprijed određene kategorije događaja (kardiovaskularni/tromboembolijski; poremećaj funkcije bubrega/zatajenje bubrega; ulkus/krvarenje iz gornjeg dijela gastrointestinalnog sustava; komplikacije kirurške rane).
In the second CABG surgery study, four pre-specified event categories were evaluated (cardiovascular/thromboembolic; renal dysfunction/renal failure; upper GI ulcer/bleeding; surgical wound complication).
U drugom ispitivanju kod operacije ugradnje arteriokoronarne premosnice procjenjivane su četiri unaprijed određene kategorije događaja (kardiovaskularni/tromboembolijski; poremećaj funkcije bubrega/zatajenje bubrega; ulkus/krvarenje iz gornjeg gastrointestinalnog sustava; komplikacije kirurške rane).
In the second CIN 3 case observed in a patient infected with HPV 51 at Day 1 (in 2 of 9 specimens); HPV 16 was detected at a Month 51 biopsy (in 1 of 9 specimens) and HPV 56 was detected in 3 of 9 specimens at Month 52 in tissue excised during LEEP.
U drugom CIN 3 slučaju zabilježenom u bolesnice inficirane tipom 51 HPV-a 1-og dana ispitivanja (u 2 od 9 uzoraka), ustanovljeni su HPV 16 biopsijom u 51-om mjesecu (u 1 od 9 uzoraka) i HPV 56 u 3 od 9 uzoraka u 52-om mjesecu u tkivu uzetom ekscizijom tijekom LEEP.
In the second clinical study, a single dose administered four months after two catch-up doses at 12-20 months of age elicited a marked increase of ELISA GMCs and OPA GMTs (when comparing the responses pre and post the last dose), indicating that two catch-up doses provide adequate priming.
U drugom kliničkom ispitivanju, jedna doza primijenjena četiri mjeseca nakon dviju doza u sklopu naknadne provedbe propuštenog ili odgođenog uobičajenog cijepljenja u dobi od 12-20 mjeseci dovela je do primjetnog povećanja ELISA GMC-a i OPA GMT-a (pri usporedbi odgovora prije i nakon posljednje doze), što pokazuje da dvije doze u sklopu naknadne provedbe propuštenog ili odgođenog uobičajenog cijepljenja omogućuju adekvatnu primarnu imunizaciju.
In the second cycle, hospitalisation is recommended at a minimum for 2 days, and clinical judgment should be based on tolerance to BLINCYTO in the first cycle.
U drugom ciklusu hospitalizacija se preporučuje tijekom najmanje 2 dana, a klinička procjena se mora temeljiti ovisno do podnošljivosti lijeka BLINCYTO u prvom ciklusu.
In the second double-blind 28- week treatment period the difference in rates between treatment groups represented a 63% (rate ratio 0.37, p<0.001) decrease relative to placebo for omalizumab patients.
U drugom dvostruko slijepom 28-tjednom razdoblju liječenja razlika u stopama između terapijskih skupina bila je 63%-tno smanjenje (omjer stopa 0,37, p<0,001) kod bolesnika liječenih omalizumabom u odnosu na placebo.
In the second field study, a group of 18-day-old embryonated eggs and a group of one-day-old chicks were vaccinated with Vectormune ND.
U drugom terenskom ispitivanju, grupa od 18 dana starih jaja s embrijem i grupa od jedan dan starih pilića cijepljene su VMP-om Vectormune ND.
In the second HL study (in patients with HL at increased risk of coming back), the average length of time patients lived before their disease got worse was around 43 months in those given Adcetris, compared with around 24 months in those given placebo.
U drugom ispitivanju HL-a (u bolesnika s HL-om s povećanim rizikom od ponovnog javljanja bolesti), bolesnici liječeni lijekom Adcetris u prosjeku su živjeli otprilike 43 mjeseca bez pogoršanja bolesti u usporedbi s otprilike 24 mjeseca u bolesnika koji su primili placebo.
In the second HL study (in patients with HL at increased risk of progressing or coming back), the main measure of effectiveness was how long patients lived without their disease getting worse.
U drugom ispitivanju HL-a (u bolesnika s HL-om s povećanim rizikom od progresije ili ponovnog javljanja bolesti), glavno mjerilo djelotvornosti bila je stopa preživljenja bolesnika bez pogoršanja bolesti.
In the second ITP study, 57 patients with ITP (baseline platelet counts ≤ 30×109 / l) aged between 18 and 65 years were treated with Privigen at 1 g/kg bw.
U drugom ITP ispitivanju 57 je bolesnika (broj trombocita na početku ispitivanja ≤30x109/1) u dobi između 18 i 65 godina liječeno Privigenom u dozi od 1 g/kg TT.
In the second ITP study, patients taking Revolade were around eight times more likely than those taking placebo to reach a platelet count of between 50,000 and 400,000 per microlitre during the six months of treatment.
U drugom ispitivanju primjene lijeka u liječenju ITP-a, vjerojatnost da će broj trombocita doseći razinu od 50 000 do 400 000/µl tijekom šest mjeseci liječenja bila je oko osam puta veća kod bolesnika koji su primali lijek Revolade nego kod onih koji su primali placebo.